Ohr Pharmaceuticals (NASDAQ: OHRP) and Tetralogic Pharmaceuticals Corp (NASDAQ:TLOG) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, dividends, risk, earnings and valuation.
This table compares Ohr Pharmaceuticals and Tetralogic Pharmaceuticals Corp’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Tetralogic Pharmaceuticals Corp||N/A||N/A||-73.81%|
Risk & Volatility
Ohr Pharmaceuticals has a beta of 0.64, suggesting that its stock price is 36% less volatile than the S&P 500. Comparatively, Tetralogic Pharmaceuticals Corp has a beta of 3, suggesting that its stock price is 200% more volatile than the S&P 500.
This is a summary of recent recommendations and price targets for Ohr Pharmaceuticals and Tetralogic Pharmaceuticals Corp, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Tetralogic Pharmaceuticals Corp||0||0||0||0||N/A|
Ohr Pharmaceuticals presently has a consensus target price of $10.00, suggesting a potential upside of 1,462.50%. Given Ohr Pharmaceuticals’ higher possible upside, research analysts clearly believe Ohr Pharmaceuticals is more favorable than Tetralogic Pharmaceuticals Corp.
Institutional & Insider Ownership
8.3% of Ohr Pharmaceuticals shares are owned by institutional investors. Comparatively, 2.7% of Tetralogic Pharmaceuticals Corp shares are owned by institutional investors. 17.4% of Ohr Pharmaceuticals shares are owned by company insiders. Comparatively, 24.0% of Tetralogic Pharmaceuticals Corp shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Valuation and Earnings
This table compares Ohr Pharmaceuticals and Tetralogic Pharmaceuticals Corp’s top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Ohr Pharmaceuticals||N/A||N/A||-$24.22 million||($0.70)||-0.91|
|Tetralogic Pharmaceuticals Corp||N/A||N/A||-$21.14 million||($1.76)||-0.01|
Ohr Pharmaceuticals is trading at a lower price-to-earnings ratio than Tetralogic Pharmaceuticals Corp, indicating that it is currently the more affordable of the two stocks.
Tetralogic Pharmaceuticals Corp beats Ohr Pharmaceuticals on 5 of the 9 factors compared between the two stocks.
Tetralogic Pharmaceuticals Corp Company Profile
TetraLogic Pharmaceuticals Corporation is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing small molecule therapeutics in oncology, infectious diseases and autoimmune diseases. The Company’s segment is the identification and development of novel small molecule therapies in oncology and infectious diseases. The Company has approximately two clinical-stage product candidates in development, such as birinapant and SHAPE. SHAPE is the Company’s histone deacetylase (HDAC) inhibitor that it is developing for topical use for the treatment of early-stage cutaneous T-cell lymphoma (CTCL). The Company is also exploring studying SHAPE in alopecia areata, an autoimmune skin disease. SHAPE has been granted the United States orphan drug designation for CTCL. Birinapant is a small molecule therapeutic that mimics Second Mitochondrial Activator of Caspases (SMAC)-mimetic, which leads to apoptosis or cell-death in damaged cells.
Receive News & Ratings for Ohr Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ohr Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.